PURPOSE: To compare the safety of regadenoson, a selective agonist of A2A adenosine receptors, combined with low-level exercise, between subjects with mild/moderate chronic obstructive pulmonary disease (COPD) and asthma referred for myocardial perfusion imaging (MPI). METHODS: We studied 116 patients, of whom 67 had COPD and 49 asthma (62 % men, mean age 68.3 ± 11.3 years, range 31 - 87 years). Patient demographics, past medical history, medications, clinical symptoms during stress and changes in blood pressure (BP) and heart rate (HR) were evaluated. RESULTS: Both groups were comparable with regard to hypertension, dyslipidaemia, diabetes and medications with the exception of a higher rate of use of anticholinergics in patients with COPD and of antileukotrienes in asthmatics (58.2 % vs. 28.6 % and 1.5 % vs. 14.3 %, respectively; all p < 0.01). There was a higher incidence of dyspnoea in COPD patients and of headache and feeling hot in asthmatic patients (40.3 % vs. 22.4 %, 6 % vs. 18.4 % and 10.4 % vs. 26.5 %, respectively; all p < 0.05). Although there was no difference in the incidence of other adverse events, we observed a higher frequency in asthmatics of flushing, dry mouth, sweating and fatigue (1.5 % vs. 6.1 %, 14.9 % vs. 24.5 %, 0 % vs. 4.1 % and 37.3 % vs. 49 %, respectively). Adverse events were self-limiting, except in three patients who suffered persistent dyspnoea (2 of 67 COPD patients; 1 of 49 asthma patients) requiring theophylline administration. We observed no significant changes in BP among either group, but there was a tendency towards a higher increase in systolic BP in COPD patients following regadenoson administration (148.3 ± 27.6 vs. 154.6 ± 31.0 mmHg, p = 0.056). CONCLUSION: This study showed a good safety profile in our series of COPD and asthma patients undergoing MPI. Regadenoson was well tolerated by all patients, with dyspnoea, headache and feeling hot showing differences between groups.
PURPOSE: To compare the safety of regadenoson, a selective agonist of A2A adenosine receptors, combined with low-level exercise, between subjects with mild/moderate chronic obstructive pulmonary disease (COPD) and asthma referred for myocardial perfusion imaging (MPI). METHODS: We studied 116 patients, of whom 67 had COPD and 49 asthma (62 % men, mean age 68.3 ± 11.3 years, range 31 - 87 years). Patient demographics, past medical history, medications, clinical symptoms during stress and changes in blood pressure (BP) and heart rate (HR) were evaluated. RESULTS: Both groups were comparable with regard to hypertension, dyslipidaemia, diabetes and medications with the exception of a higher rate of use of anticholinergics in patients with COPD and of antileukotrienes in asthmatics (58.2 % vs. 28.6 % and 1.5 % vs. 14.3 %, respectively; all p < 0.01). There was a higher incidence of dyspnoea in COPDpatients and of headache and feeling hot in asthmatic patients (40.3 % vs. 22.4 %, 6 % vs. 18.4 % and 10.4 % vs. 26.5 %, respectively; all p < 0.05). Although there was no difference in the incidence of other adverse events, we observed a higher frequency in asthmatics of flushing, dry mouth, sweating and fatigue (1.5 % vs. 6.1 %, 14.9 % vs. 24.5 %, 0 % vs. 4.1 % and 37.3 % vs. 49 %, respectively). Adverse events were self-limiting, except in three patients who suffered persistent dyspnoea (2 of 67 COPDpatients; 1 of 49 asthmapatients) requiring theophylline administration. We observed no significant changes in BP among either group, but there was a tendency towards a higher increase in systolic BP in COPDpatients following regadenoson administration (148.3 ± 27.6 vs. 154.6 ± 31.0 mmHg, p = 0.056). CONCLUSION: This study showed a good safety profile in our series of COPD and asthmapatients undergoing MPI. Regadenoson was well tolerated by all patients, with dyspnoea, headache and feeling hot showing differences between groups.
Authors: H William Strauss; D Douglas Miller; Mark D Wittry; Manuel D Cerqueira; Ernest V Garcia; Abdulmassi S Iskandrian; Heinrich R Schelbert; Frans J Wackers; Helena R Balon; Otto Lang; Josef Machac Journal: J Nucl Med Technol Date: 2008-08-14
Authors: B A Walker; M A Jacobson; D A Knight; C A Salvatore; T Weir; D Zhou; T R Bai Journal: Am J Respir Cell Mol Biol Date: 1997-05 Impact factor: 6.914
Authors: Deborah H Kwon; Manuel D Cerqueira; Ron Young; Penny Houghtaling; Elizabeth Lieber; Venu Menon; Richard C Brunken; Wael A Jaber Journal: J Nucl Cardiol Date: 2010-04-23 Impact factor: 5.952
Authors: Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang Journal: J Nucl Cardiol Date: 2007 Sep-Oct Impact factor: 5.952
Authors: Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu Journal: J Nucl Cardiol Date: 2008-04-14 Impact factor: 5.952
Authors: Victor M Moles; Thomas Cascino; Ashraf Saleh; Krasimira Mikhova; John J Lazarus; Michael Ghannam; Hong J Yun; Matthew Konerman; Richard L Weinberg; Edward P Ficaro; James R Corbett; Vallerie V McLaughlin; Venkatesh L Murthy Journal: J Nucl Cardiol Date: 2016-11-28 Impact factor: 5.952
Authors: A M Bucher; C N De Cecco; U J Schoepf; R Wang; F G Meinel; S R Binukrishnan; J V Spearman; T J Vogl; B Ruzsics Journal: Br J Radiol Date: 2014-08-19 Impact factor: 3.039
Authors: Carlos Salgado-Garcia; Amelia Jimenez-Heffernan; Juana Lopez-Martin; Manuela Molina-Mora; Tarik Aroui; Elena Sanchez de Mora; Carlos Ramos-Font; Francisco Rivera de Los Santos; Carlos Ruiz-Frutos Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-25 Impact factor: 9.236